Biotechnology · Waltham, Massachusetts, United States
$7.44
-4.74% (-$0.37)2026-07-10
Smart-Money SignalDistribution · 42/100— Insiders are net sellers over 90 days (-$31K, 5 sales vs 1 buy)
Revenue$1.0M
Net Income-$40.6M
EPS$-0.75
Market Cap$404.9M
Price Performance
Historical data including institutional events
Company Profile
E
E. Sutherland
CEO & Executive Director
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
